4778 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 15
Sirisoma et al.
(8) (a) van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.;
Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory,
S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic
ABT-737 targets selective Bcl-2 proteins and efficiently induces
apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006, 10,
389–399. (b) Tang, G.; Yang, C.-Y.; Nikolovska-Coleska, Z.; Guo,
J.; Qiu, S.; Wang, R.; Gao, W.; Wang, G.; Stuckey, J.; Krajewski,
K.; Jiang, S.; Roller, P. P.; Wang, S. Pyrogallol-based molecules as
potent inhibitors of the antiapoptotic Bcl-2 proteins. J. Med. Chem.
2007, 50, 1723–1726.
(9) (a) Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Farnie, G.; Golding,
B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; Kallblad, P.; Kemp,
S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.;
Reid, R. J.; Saravanan, K.; Willems, H. M. G.; Lunec, J. Small-
molecule inhibitors of the MDM2-p53 protein-protein interaction
based on an isoindolinone scaffold. J. Med. Chem. 2006, 49, 6209–
6221. (b) Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu,
S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller,
P. P.; Wang, S. Structure-based design of spiro-oxindoles as potent,
specific small-molecule inhibitors of the MDM2-p53 interaction.
J. Med. Chem. 2006, 49, 3432–3435.
(10) Chen, J.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Wang, S. Design,
synthesis, and characterization of new embelin derivatives as potent
inhibitors of X-linked inhibitor of apoptosis protein. Bioorg. Med.
Chem. Lett. 2006, 16, 5805–5808.
(11) Li, L.; Thomas, R. M.; Suzuki, H.; De Brabander, J. K.; Wang, X.;
Harran, P. G. A small molecule Smac mimic potentiates TRAIL- and
TNFalpha-mediated cell death. Science 2004, 305, 1471–1474.
(12) Putt, K. S.; Chen, G. W.; Pearson, J. M.; Sandhorst, J. S.; Hoagland,
M. S.; Kwon, J. T.; Hwang, S. K.; Jin, H.; Churchwell, M. I.; Cho,
M. H.; Doerge, D. R.; Helferich, W. G.; Hergenrother, P. J. Small-
molecule activation of procaspase-3 to caspase-3 as a personalized
anticancer strategy. Nat. Chem. Biol. 2006, 2, 543–550.
(13) Cai, S. X.; Zhang, H.-Z.; Guastella, J.; Drewe, J.; Yang, W.; Weber,
E. Design and synthesis of rhodamine 110 derivative and caspase-3
substrate for enzyme and cell-based fluorescent assay. Bioorg. Med.
Chem. Lett. 2001, 11, 39–42.
(14) Cai, S. X.; Drewe, J.; Kasibhatla, S. A chemical genetics approach
for the discovery of apoptosis inducers: from phenotypic cell based
HTS assay and structure-activity relationship studies, to identification
of potential anticancer agents and molecular targets. Curr. Med. Chem.
2006, 13, 2627–2644.
(15) Zhang, H.-Z.; Kasibhatla, S.; Wang, Y.; Herich, J.; Guastella, J.; Tseng,
B.; Drewe, J.; Cai, S. X. Discovery, Characterization and SAR of
gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg.
Med. Chem. 2004, 12, 309–317.
(16) Kasibhatla, S.; Jessen, K.; Maliartchouk, S.; Wang, J.; English, N.;
Drewe, J.; Qui, L.; Archer, S.; Ponce, A.; Sirisoma, N.; Jiang, S.;
Zhang, H.-Z.; Gehlsen, K.; Cai, S. X.; Green, D. R.; Tseng, B. A
novel role for transferrin receptor in triggering apoptosis when targeted
with gambogic acid. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12095–
12100.
(20) (a) Kasibhatla, S.; Gourdeau, H.; Meerovitch, K.; Drewe, J.; Reddy,
S.; Qiu, L.; Zhang, H.; Bergeron, F.; Bouffard, D.; Yang, Q.; Herich,
J.; Lamothe, S.; Cai, S. X.; Tseng, B. Discovery and mechanism of
action of a novel series of apoptosis inducers with potential vascular
targeting activity. Mol. Cancer Ther. 2004, 3, 1365–1374. (b)
Gourdeau, H.; Leblond, L.; Hamelin, B.; Desputeau, C.; Dong, K.;
Kianicka, I.; Custeau, D.; Bourdeau, C.; Geerts, L.; Cai, S. X.; Drewe,
J.; Labrecque, D.; Kasibhatla, S.; Tseng, B. Antivascular and antitumor
evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-
chromenes, a novel series of anticancer agents. Mol. Cancer Ther.
2004, 3, 1375–1383.
(21) Elslager, E. F.; Hess, C.; Johnson, J.; Ortwine, D.; Chu, V.; Werbel,
L. M. Synthesis and antimalarial effects of N2-aryl-N4-[(dialkylami-
no)alkyl]- and N4-aryl-N2-[(dialkylamino)alkyl]-2,4-quinazolinedi-
amines. J. Med. Chem. 1981, 24, 127–140.
(22) Badiger, V. V.; Nargund, K. S. Substituted phenyl quinazolyl ethers.
J. Karnatak UniV. 1960, 5, 10–17.
(23) Cai, S. X.; Nguyen, B.; Jia, S.; Herich, J.; Guastella, J.; Reddy, S.;
Tseng, B.; Drewe, J.; Kasibhatla, S. Discovery of substituted N-phenyl
nicotinamides as potent inducers of apoptosis using a cell- and caspase-
based high throughput screening assay. J. Med. Chem. 2003, 46, 2474–
2481.
(24) Mayer, L. D.; Lim, K. T.; Hartley, D. Identification of two distinct
intracellular sites that contribute to the modulation of multidrug
resistance in P388/ADR cells expressing P-glycoprotein. J. Exp. Ther.
Oncol. 2002, 2, 107–120.
(25) Denny, W. A. The 4-anilinoquinazoline class of inhibitors of the erbB
family of receptor tyrosine kinases. Farmaco 2001, 56, 51–56.
(26) (a) Klutchko, S. R.; Zhou, H.; Winters, R. T.; Tran, T. P.; Bridges,
A. J.; Althaus, I. W.; Amato, D. M.; Elliott, W. L.; Ellis, P. A.; Meade,
M. A.; Roberts, B. J.; Fry, D. W.; Gonzales, A. J.; Harvey, P. J.;
Nelson, J. M.; Sherwood, V.; Han, H.-K.; Pace, G.; Smaill, J. B.;
Denny, W. A.; Showalter, H. D. H. Tyrosine kinase inhibitors. 19.
6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-
d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine
kinase receptors. J. Med. Chem. 2006, 49, 1475–1485. (b) Hennequin,
L. F.; Allen, J.; Breed, J.; Curwen, J.; Fennell, M.; Green, T. P.;
Lambert-van der Brempt, C.; Morgentin, R.; Norman, R. A.; Olivier,
A.; Otterbein, L.; Ple, P. A.; Warin, N.; Costello, G. N-(5-Chloro-
1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahy-
dro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective,
orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem.
2006, 49, 6465–6488. (c) Jung, F. H.; Pasquet, G.; Lambert-van der
Brempt, C.; Lohmann, J.-J. M.; Warin, N.; Renaud, F.; Germain, H.;
De Savi, C.; Roberts, N.; Johnson, T.; Dousson, C.; Hill, G. B.;
Mortlock, A. A.; Heron, N.; Wilkinson, R. W.; Wedge, S. R.; Heaton,
S. P.; Odedra, R.; Keen, N. J.; Green, S.; Brown, E.; Thompson, K.;
Brightwell, S. Discovery of nove l and potent thiazoloquinazolines as
selective eaurora A and B kinase inhibitors. J. Med. Chem. 2006, 49,
955–970.
(27) Bridges, A. J. Chemical inhibitors of protein kinases. Chem. ReV. 2001,
101, 2541–2572.
(28) Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody,
D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5.
Synthesis and structure-activity relationships for 4-[(phenylmethy-
l)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-
triphosphate binding site inhibitors of the tyrosine kinase domain of
the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482–
3487.
(29) Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael,
A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A.
Tyrosine kinase inhibitors. 8. An unusually steep structure-activity
relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazo-
line (PD 153035), a potent inhibitor of the epidermal growth factor
receptor. J. Med. Chem. 1996, 39, 267–276.
(17) Zhang, H.-Z.; Kasibhatla, S.; Kuemmerle, J.; Kemnitzer, W.; Oliis-
Mason, K.; Qui, L.; Crogran-Grundy, C.; Tseng, B.; Drewe, J.; Cai,
S. X. Discovery and structure activity relationship of 3-aryl-5-aryl-
1,2,4-oxadiazoles as a new series of apoptosis inducers and potential
anticancer agents. J. Med. Chem. 2005, 48, 5215–5223.
(18) Jessen, K.; English, N.; Wang, J.; Qui, L.; Brand, R.; Maliartchouk,
S.; Drewe, J.; Kuemmerle, J.; Zhang, H.-Z.; Gehlsen, K.; Tseng, B.;
Cai, S. X.; Kasibhatla, S. Identification of tail interacting protein
(TIP47), an IGFII receptor binding protein as the molecular target for
tumor selective apoptosis-inducing agents, 3,5-diaryl-[1,2,4]-oxadia-
zoles. Mol. Cancer Ther. 2005, 4, 761–771.
(19) (a) Kemnitzer, W.; Kasibhatla, S.; Jiang, S.; Zhang, H.; Wang, Y.;
Zhao, J.; Jia, S.; Herich, J.; Labreque, D.; Storer, R.; Meerovitch, K.;
Bouffard, D.; Rej, R.; Denis, R.; Blais, C.; Lamothe, S.; Attardo, G.;
Gourdeau, H.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 4-aryl-
4H-chromenes as new series of apoptosis inducers using a cell- and
caspase-based high-throughput screening assay. 1. Structure-activity
relationships of the 4-aryl group. J. Med. Chem. 2004, 47, 6299–6310.
(b) Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Zhao, J.; Crogan-
Grundy, C.; Xu, L.; Lamothe, S.; Gourdeau, H.; Denis, R.; Tseng,
B.; Kasibhatla, S.; Cai, S. X. Discovery of 4-aryl-4H-chromenes as
new series of apoptosis inducers using a cell- and caspase-based high-
throughput screening assay. 3. Structure-activity relationships of fused
rings at the 7,8-positions. J. Med. Chem. 2007, 50, 2858–2864. (c)
Kemnitzer, W.; Drewe, J.; Jiang, S.; Zhang, H.; Crogan-Grundy, C.;
Labreque, D.; Bubenick, M.; Attardo, G.; Denis, R.; Lamothe, S.;
Gourdeau, H.; Tseng, B.; Kasibhatla, S.; Cai, S. X. Discovery of 4-aryl-
4H-chromenes as a new series of apoptosis inducers using a cell- and
caspase-based high throughput screening assay. 4. Structure-activity
relationships of N-alkyl-substituted pyrrole fused at the 7-, 8-positions.
J. Med. Chem. 2008, 51, 417–423.
(30) Gazit, A.; Chen, J.; App, H.; McMahon, G.; Hirth, P.; Chen, I.;
Levitzki, A. Tyrphostins IV: highly potent inhibitors of EGF receptor
kinase. Structure-activity relationship study of 4-anilinoquinazolines.
Bioorg. Med. Chem. 1996, 4, 1203–1207.
(31) Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.;
Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.;
Pervin, A.; Tseng, B.; Carlson, R. O.; Pleiman, C. M. MPC-6827: A
small molecule inhibitor of microtubule formation that is not a substrate
for multidrug resistance pumps. Cancer Res. 2007, 67, 5865–5871.
(32) Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell,
A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.;
Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique
structure for epidermal growth factor receptor bound to GW572016
(Lapatinib): relationships among protein conformation, inhibitor off-
rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652–
6659.
(33) Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the
epidermal growth factor receptor kinase domain alone and in